Indian generics attracting investor attention in search of profitable opportunities

Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy.

With overall mergers and acquisitions (M&A) deal value hitting a record $148 billion between January to September 2022, surpassing the previous annual record of $132 billion posted in 2018, the first nine months of last year in terms of the number of M&A deals has paved the way for a stellar 2023 and have kept the sector buoyant, reports The Pharma Letter’s India correspondent.

Though the market was caught off guard by geopolitical uncertainty and inflation in the second half of 2022, private equity (PE) activity has been kicked into high gear from the start of 2023.